Codexis, Inc. (NASDAQ:CDXS - Get Free Report) CEO Alison Moore sold 10,651 shares of the stock in a transaction dated Monday, November 16th. The stock was sold at an average price of $1.14, for a total transaction of $12,142.14. Following the transaction, the chief executive officer directly owned 233,520 shares of the company's stock, valued at $266,212.80. This represents a 4.36% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Alison Moore also recently made the following trade(s):
- On Monday, October 12th, Alison Moore sold 6,335 shares of Codexis stock. The shares were sold at an average price of $1.36, for a total value of $8,615.60.
Codexis Stock Performance
NASDAQ CDXS traded up $0.08 on Wednesday, hitting $1.15. 1,465,677 shares of the company's stock were exchanged, compared to its average volume of 1,391,405. The firm has a market cap of $126.04 million, a price-to-earnings ratio of -5.75 and a beta of 2.38. The firm's 50-day moving average price is $1.28 and its two-hundred day moving average price is $1.78. Codexis, Inc. has a fifty-two week low of $0.90 and a fifty-two week high of $2.98. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.81 and a quick ratio of 2.99.
Codexis (NASDAQ:CDXS - Get Free Report) last posted its quarterly earnings results on Thursday, November 12th. The biotechnology company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.10) by $0.02. Codexis had a negative return on equity of 43.24% and a negative net margin of 21.77%. The business had revenue of $19.26 million during the quarter, compared to analysts' expectations of $18.72 million. On average, research analysts expect that Codexis, Inc. will post -0.37 EPS for the current year.
Analysts Set New Price Targets
CDXS has been the subject of a number of research analyst reports. Wall Street Zen upgraded shares of Codexis from a "sell" rating to a "hold" rating in a report on Saturday. Piper Sandler decreased their price objective on shares of Codexis from $9.00 to $8.00 and set an "overweight" rating on the stock in a report on Monday, August 17th. Stephens restated an "overweight" rating and set a $5.00 target price on shares of Codexis in a research report on Monday. Weiss Ratings raised shares of Codexis from a "sell (e+)" rating to a "sell (d-)" rating in a report on Friday, October 23rd. Finally, Benchmark reiterated a "hold" rating on shares of Codexis in a research report on Thursday, August 20th. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, Codexis currently has a consensus rating of "Hold" and a consensus price target of $6.00.
Get Our Latest Stock Analysis on CDXS
Institutional Inflows and Outflows
Hedge funds have recently made changes to their positions in the company. Goldman Sachs Group Inc. grew its holdings in Codexis by 93.3% during the 3rd quarter. Goldman Sachs Group Inc. now owns 840,866 shares of the biotechnology company's stock valued at $1,169,000 after buying an additional 405,942 shares during the last quarter. Empowered Funds LLC acquired a new position in shares of Codexis in the third quarter worth $160,000. Private Advisor Group LLC purchased a new stake in shares of Codexis in the third quarter valued at $1,677,000. Aberdeen Group plc lifted its position in shares of Codexis by 59.5% in the third quarter. Aberdeen Group plc now owns 10,797,702 shares of the biotechnology company's stock valued at $15,009,000 after acquiring an additional 4,027,748 shares in the last quarter. Finally, Prescott Group Capital Management L.L.C. purchased a new stake in shares of Codexis in the third quarter valued at $556,000. Hedge funds and other institutional investors own 78.54% of the company's stock.
About Codexis
(
Get Free Report)
Codexis, Inc. is a biotechnology company that develops engineered enzymes for pharmaceutical and other manufacturing applications. Founded in 2002 and based in Redwood City, California, the company uses its protein-engineering platform, CodeEvolver, to design enzymes with properties suited to specific production processes. Codexis supplies enzymes and related development services for the manufacture of small-molecule drugs and other products. It also develops its ECO Synthesis platform, which uses enzymes to support the production of oligonucleotide therapeutics, including RNA-based medicines.
Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Codexis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Codexis wasn't on the list.
While Codexis currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.